title: Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
abstract: OBJECTIVE
  To compare the efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring (CGM) in a single-day treatment setting.
  
  
  METHODS
  This was a post hoc analysis of a randomized crossover study comparing the efficacy of sitagliptin, mitiglinide and the combination of these two drugs. Twenty-four hour CGM was performed before and after a single-day treatment with each drug alone or in combination.
  
  
  RESULTS
  Mean glucose levels were decreased in all groups. The average of three postprandial glucose excursions AUC (average of all three 4-h postprandial periods throughout the day) (AUCpp-average) decreased in the mitiglinide and combination treatment groups, but not in the sitagliptin group. The lowering effect on AUCpp-average was greater in patients given mitiglinide (-47 mg/dl, p < 0.001) or combination treatment (-66 mg/dl, p < 0.001) compared with sitagliptin alone (-18 mg/dl). The reduction in mean amplitude of glycemic excursion was greater with mitiglinide (-29.3 mg/dl, p < 0.001) and combination treatment (-28.3 mg/dl, p < 0.01) than with sitagliptin alone (-8.9 mg/dl).
  
  
  CONCLUSIONS
  Mitiglinide or combination treatment resulted in lower glycemic variability and postprandial glucose excursion than sitagliptin alone; however, the results of this single-day pharmacodynamics study cannot be generalized to a clinical setting.
authors.affiliation: Sungkyunkwan University School of Medicine, Samsung Medical Center, Department of Medicine , Seoul , South Korea +82 2 3410 1580 ; +82 2 3410 3849 ; jaehyeon@skku.edu ; wooseong.huh@samsung.com.
authors.forename: Jong-Ha
authors.initials: JH
authors.lastname: Baek
authors.forename: Sang-Man
authors.initials: SM
authors.lastname: Jin
authors.forename: Kohei
authors.initials: K
authors.lastname: Kaku
authors.forename: Jin-Ah
authors.initials: JA
authors.lastname: Jung
authors.forename: Jung-Ryul
authors.initials: JR
authors.lastname: Kim
authors.forename: Jae-Wook
authors.initials: JW
authors.lastname: Ko
authors.forename: Min-Ji
authors.initials: MJ
authors.lastname: Kim
authors.forename: Soo-Youn
authors.initials: SY
authors.lastname: Lee
authors.forename: Woo-seong
authors.initials: WS
authors.lastname: Huh
authors.forename: Jae Hyeon
authors.initials: JH
authors.lastname: Kim
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054833:Isoindoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D011446:Prospective Studies; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D054833:Isoindoles; D011719:Pyrazines; D014230:Triazoles; C087255:mitiglinide; D000068900:Sitagliptin Phosphate
keywords: continuous glucose monitoring; glycemic variability; mitiglinide; postprandial hyperglycemia; sitagliptin